TABLE 4.
OSCC‐associated autoantibodies as biomarkers for OSCC
| Author/Year | Source of Biomarkers | Method | Sample size | Antigens Identified | Findings |
|---|---|---|---|---|---|
| Pillai et al. 116 | Saliva and Serum | Systematic Review | N/D | p53 and Hsp70 | Increased in OSCC compared to Control |
| Chu et al. 119 | Saliva | LC–MS/MS | 30 | CPPED1, GLUD1, LMAN2, PTGR1, RAB13, RAC1, UQCRC2 and p53 | Increased in OSCC compared to Control, especially in early stage OSCC. |
| Hsueh et al. 110 | Saliva | Multiplexed Immunoassay | 300 | ANXA2, CA2, ISG15, KNG1, MMP1, MMP3, PRDX2, SPARC, and HSPA5 |
Increased in OSCC compared to Control, especially in early stage OSCC ANXA2, KNG1, and MMP1 IgM were significantly higher in relapsed OSCC group, compared to primary OSCC group |
| Tseng et al. 115 | Saliva | LC‐MRM‐MS | 337 | ANXA2, CA2, ISG15, KNG1, MMP1, MMP3, PRDX2, SPARC, and HSPA5 | Increased in OSCC compared to Control |
| Wu et al. 114 | Saliva | Multiplexed immunoassay | 348 | p53, survivin, Hsp60, and RPLP0 | Increased in OSCC compared to Control, especially in early stage OSCC; Late stage OSCC group not significant different compared to Control |
| Liu et al. 117 | Plasma | ELISA | 193 | CD47 | Increased in OSCC compared to Control; Anti‐CD47 autoantibody plasma induces apoptosis via p‐AKT (in vitro) |
| Lin et al. 224 | Serum | Immunoassay | 4 | p53 | Increased in OSCC compared to Control |
| Schutt et al. 225 | Tissue and Serum | IHC and Elisa | 59 | Sperm Protein 17 (SP17) | Increased in OSCC compared to Control |
| Liu et al. 118 | In vitro | ELISA | N/A | ATP‐binding cassette subfamily C member 3 (ABCC3) | Plasma containing the autoantibody inducted apoptosis and cell cycle arrest |
Abbreviation: N/D, not disclosed.